Inhibition of platelet aggregation by the recombinant cysteine-rich domain of the hemorrhagic snake venom metalloproteinase, atrolysin A

被引:64
作者
Jia, LG
Wang, XM
Shannon, JD
Bjarnason, JB
Fox, JW [1 ]
机构
[1] Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA
[2] Univ Iceland, Inst Sci, IS-107 Reykjavik, Iceland
关键词
snake venoms; metalloproteinases; platelet aggregation; cysteine-rich domain;
D O I
10.1006/abbi.1999.1517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The P-III class of venom metalloproteinases has, in addition to the proteinase domain, a disintegrin-like domain and a cysteine-rich domain. Recent evidence has shown that the nonproteinase domains of the P-III class of hemorrhagic metalloproteinases function in the inhibition of platelet aggregation by blocking essential procoagulant integrins on platelets. A specific role for the highly conserved cysteine-rich domain has yet to be described. In this study, we expressed the cysteine-rich domain from the hemorrhagic metalloproteinase atrolysin A and demonstrated its ability to inhibit collagen-stimulated platelet aggregation. Additionally, the cysteine-rich domain was shown to interact with MG-63 cells to inhibit adhesion to collagen I. These data suggest a functional role for the cysteine-rich domain of the P-III toxins in the observed coagulopathy by targeting the toxin to platelets and inhibiting collagen-stimulated platelet aggregation. These characteristics may function to synergistically increase the hemorrhagic effect of the toxins. (C) 2000 Academic Press.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 25 条
[1]   BINDING OF NIDOGEN AND THE LAMININ-NIDOGEN COMPLEX TO BASEMENT-MEMBRANE COLLAGEN TYPE-IV [J].
AUMAILLEY, M ;
WIEDEMANN, H ;
MANN, K ;
TIMPL, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 184 (01) :241-248
[2]   DEGRADATION OF EXTRACELLULAR-MATRIX PROTEINS BY HEMORRHAGIC METALLOPROTEINASES [J].
BARAMOVA, EN ;
SHANNON, JD ;
BJARNASON, JB ;
FOX, JW .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1989, 275 (01) :63-71
[3]  
BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345
[4]  
BJARNASON JB, 1988, BIOL CHEM H-S, V369, P121
[5]  
BJARNASON JB, 1994, J PHARM THER, V62, P321
[6]  
BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
[7]  
CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159
[8]   JARARHAGIN AND JARACETIN - NOVEL SNAKE-VENOM INHIBITORS OF THE INTEGRIN COLLAGEN RECEPTOR, ALPHA(2)BETA(1) [J].
DELUCA, M ;
WARD, CM ;
OHMORI, K ;
ANDREWS, RK ;
BERNDT, MC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (02) :570-576
[9]   BINDING INTERACTIONS OF KISTRIN WITH PLATELET GLYCOPROTEIN-IIB-IIIA - ANALYSIS BY SITE-DIRECTED MUTAGENESIS [J].
DENNIS, MS ;
CARTER, P ;
LAZARUS, RA .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 1993, 15 (03) :312-321
[10]  
FOX JW, 1995, METHODS ENZYMOLOGY E, V248, P369